Geurts, Sven
Tilly, Martijn J.
Arshi, Banafsheh
Stricker, Bruno H. C.
Kors, Jan A.
Deckers, Jaap W.
de Groot, Natasja M. S.
Ikram, M. Arfan
Kavousi, Maryam http://orcid.org/0000-0001-5976-6519
Funding for this research was provided by:
Erasmus Universitair Medisch Centrum Rotterdam
Erasmus Universiteit Rotterdam
ZonMw
the Research Institute for Diseases in the Elderly
Ministerie van Onderwijs, Cultuur en Wetenschap
Ministerie van Volksgezondheid, Welzijn en Sport
the European Commission
the Municipality of Rotterdam
Hartstichting (03-004-2021-T050)
Article History
Received: 19 April 2022
Accepted: 20 July 2022
First Online: 13 August 2022
Declarations
:
: Ikram reports consulting fees from BioGen Inc. The remaining authors have no disclosures to report.
: The Rotterdam Study complies with the Declaration of Helsinki and has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272–159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; ExternalRef removed) and into the WHO International Clinical Trials Registry Platform (ICTRP; ExternalRef removed) under shared catalog number NL6645/NTR6831.
: For the longitudinal study, all participants provided written informed consent to participate, prior to inclusion, in the study and to have their information obtained from treating physicians. The Mendelian randomization study has been conducted using publicly available summary statistics, so no original data were collected for this bidirectional MR study. Ethical approval and informed consent from each participant in the studies included in the investigation can be found in the original publications. The analysis of other publicly available summary statistics does not require additional ethical approval.